on pipeline. to our provide I from everyone. Thanks, the Rich and good more detail like morning, highlights recent would
with pleased the date have made progress we to are vopra. particularly with We
with EMERGE cell PD-X in lung underway. II with of or cancer patients Phase non-small ipi is experienced trial in Our combination vopra cancer bladder
PD-LX growing or inhibitor. PD-X of for inhibitors These no move standard of patient established few as with populations therapy options patients represent PD-X after earlier of a rapidly unmet into area progress lines need and who care a
of but have to made great patients majority inhibitors therapy. not PD-X unfortunately the respond strides do
cells of activity CDX help may unmet focusing impact primary we of the cells the on believe need. that inhibitors PD-X role this critical CDX address As
by fundamental as This prior founders from ICOS in supports trial to vopra science ipi reverse inducing cells The administration. upon hi science trial. open-label well of analysis our multicenter EMERGE T CDX the ICONIC our role translational the as builds the
that hi demonstrated ICOS ipi T that founders hi with CDX were Our T induced outcomes levels patients cells ICOS and cells. in seen of clinical improved sustained CDX
CDX are demonstrated also that PD-X induced ICOS not cells We hi inhibitors. by T
outcomes combination hi associated alone with CDX improved of In activation ICOS patients ICONIC, treated and nivo cells. expansion that we or were with sustained T demonstrated with in vopra in emergence,
activity cells T levels high indicated of already that Additional CDX experiments only exert ICOS. that vopra have its on can
ICOS trial strategy vopra CDX cells combination based The of our dosing the of and a ipi understanding EMERGE new ipi by includes induction vopra. effector and of and kinetics on T hi sequencing of
As a study Rich optimize addresses Combinations response. point ICOS the but mentioned, optimizes critical which and This co-administered, the it IO strategy, the SITC sequencing CDX typically rationale in our hi schedule both agonist is for best mechanistic view critical are combination immune field. Saturday to dosing dosing poster to our we and T and in on context provide the biology. the and the will understand scientific believe cells
with work to continue outstanding this our to happy are founders We in regard.
endpoints non-small to overall survival expect and patients endpoint survival. we include stage cancer EMERGE, is initial progression-free XX up enroll primary and of of rate with to the safety, secondary response response, lung cancer. or cell In duration overall The bladder
close important of cell Additional ICOS emergence hi assessments will and CDX range biomarkers. of monitoring include a T other
in XX clinical We patients for relationships biomarker expect XXXX. report preliminary to data, to up outcomes including EMERGE to efficacy and
baseline a analyze Rich the predictive patients. without inhibitor. right been trial and the for As and outcomes planning of to in reverse of our several finding dedication mentioned, II the hi ICONIC of ICONIC, we to have identify a biomarkers, vopra, vopra intensive CDX using predictive biomarker PD-X translational relationship In T the Phase combination are between ICOS would likely right patients, analysis not benefit immunotherapies the the cells additional more clinical of This data a the potential associated the possible and including we to stages vopra studies from
this emergence those patients T between looked from benefit a more vopra a predictive to are We of of biomarker combination those clinical CDX ICOS identify a that Through showed and who believe we identified benefits and who hi not. patients, likely analysis, we differences and who may did PD-X for cells have inhibitor.
We will studies clinical few new approach. months in next on provide the more including biomarker details the
Turning will tomorrow now we data preliminary be to JTX-XXXX, presenting safety efficacy encouraging at and SITC.
Jounce. inhibitor to combination in trials predictive pipeline We two the to The the a other biomarker our are product agents PD-X forward with vopra step to combination is with have owned from JTX-XXXX very as in sufficient for major our conduct clinical in candidates, pleased the of including for use ability new wholly data trial. support
translational promise analyses. date to the made have a reverse platform science entire is translational and and we our progress, our strength to pipeline The across testament of
of towards as immunotherapies We continue to we patients. long-lasting and focus on the mechanistic science our bringing work to benefits cancer meaningful underlying
Now, a the for results. to third like of I Kim to call Kim? discussion turn over would quarter financial our
